1 2008 2 Slywotzky and Morrison 1997 Slywotzky 20021999 20041999,2001,2006 1999 3 3 1997 2007 10 2,550 6,674 2.6 1 2007 2,878 2 12007
2 15 658 39 20 3 13 2 OTC 8 2,294 6 6,108 3 6,911 4 10 15,900 5 9 17 1 200 300 6 94 2 8 7 2008 44 8 14 3,480 9 2 3 2005 4 5 20092008.11 6 72008.3.31 8 2009 4 44 92008 3 39 2008.12.26
3 2006 2007 63 56% 59% 39% 17% 13% 23% 26% 16% 6% IMS Health, MIDAS, New Market Segmentation, RX only MAT Dec 2006, IMS Strategic Management Review 2006, Perspectives on the Global Pharmaceutical Market, 1 40 17 10 1 2006 4 2007 6 2007 2012 30 2008 4 11 2 12 5000 13 200 300 102006 9 1 56.7 11 33.1 18 12 18 22.1 2005 13 30 12008.9.15
4 15 1 349 8152 5137 14 M&A 15 5 68 16 2 3 376 41 30 7.98 115 315 53 17 5.40 47 323 37 13 4.02 30 374 56 17 n.a. 18 n.a. 4 209 12 13 6.22 43 2008 3 2007 11 17 18 141 110 15 100 13 162008 3 39 2008.12.26 17 19 3 http://www.taiyo-yakuhin.com/ news/080205.html 18 2008 40 2008.2.22
5 2008 635 1.3 1 5 115 376 790 3 4 5
6 15 19 1975 952 1996 6,671 2007 12.1 20 21 21,677 1 22 10 20 1,374,802 37,631 278,631 20,130 1,096,171 17,501 673,048 13,452 423,123 4,048 536,415 3,413 355,454 1,739 275,788 3,221 605,487 30,954 15,717 5,708 790 684 79.7 46.5% 49.0% 35.8% 30.8% 10.8% 39.0% 9.1% 25.9% 4.6% 20.1 8.6 7.4% 8.7% 87.5 47.6 66 149 26.6% 80.1% 2.3% 6.8% 15.6% 4.5% 19 69 2009 4 20 2008.12 21 9.15 IT 5.16 4.23 2.74 3.9 2008 http://www.nikkei4946.com/today/0810/07.html 22
7 6 2,758 32 2 20.1 8.6 79.7 46.5 26.6 80.1 5 2 23 24 30 M A 23 2009.4.13 242006.10.26 http://news.livedoor.com/article/detail/2628421/
8 15 25 26 PBM Pharmacy Benefits Manager 27 PBM 28 3 69 3 29 7 30 6 49.0 35.8 PBR MS Medical Marketing Specialist MR Medical Representatives MR MS MR MS DPC 31 MR 25 26 27 PBM 3 2 28p.12 29 3 2 3 69 3 70 74 2 3 75 1 3 30IR 16 3 31 1 Diagnosis Procedure Combination
9 32 2003 4 1700 230 10 33 1 66 149 2008 3 2 32 30 1 2008.9.15 332008.8.26
10 15 34 3 9 MR MS 2008 4 16 35 MR 342009.4.13 35 2008 10 1 IMF
11 2 3 1 2 1
12 15 2007 2008.3.21 http://www.pp.u-tokyo.ac.jp/courses/2007/13090/documents/13090-2.pdf 1999 2004 1999 2001 2006 2009 2010 Porter M.E. 1980, Competitive Strategy: Techniques for Analyzing Industries and Competitors, The Free Press. 1982 Slywotzky J.A. and D.J. Morrison, 1997, The Profit Zone: How Strategic Business Design Will Lead You to Tomorrow s Profits Time Books. 1999 Slywotzky J.A. 2002, The Art of Profitability Warner Business 2008 2008 No.39, pp.11-27 The Health Strategies Consultancy LLC Follow The Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain,March 2005 http://www.kff.org/rxdrugs/upload/follow-the-pill-understanding-the-u-s-commercial-pharmaceutical-supply-chain- Report.pdf A Business model for Generic Pharmaceutical Companies: Comparison between Takeda Pharmaceutical Company and Sawai Pharmaceutical Company Yuko Oki Hideo Yamada ABSTRACT Compared to the pharmaceutical companies that produce new drugs, generic drugs companies are assumed more profitable with small amounts of R&D costs. Through the case studies between Takeda and Sawai Pharmaceutical Company, we verified generic drugs companies have to invest for lots of products lines for various kinds of drugs and have to pay rake-off for wholesales, therefore the company s profit is not as much as new drug s one. Supported by the government policy, market of generic drugs in Japan has increased in size rapidly. Since it began to attract big domestic and foreign pharmaceutical companies, small sized generic drugs companies in Japan have had to establish more profitable business model for their competitive advantages.